
    
      The purpose of the study is to evaluate efficacy, safety, and pharmacokinetics (PK) of oral
      Plecanatide 0.5, 1.0 and 1.5 mg tablets dosed once a day as compared to matching placebo,
      when administered for 8 weeks in adolescents with chronic idiopathic constipation.

      This study will consist of a 4-week screening period, 8 weeks of treatment, and a 2-week
      follow-up. The study will assess the effects of Plecanatide on bowel movement frequency and
      other clinical features of CIC.
    
  